Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 28:12:873903.
doi: 10.3389/fonc.2022.873903. eCollection 2022.

The Role of RNA Methyltransferase METTL3 in Normal and Malignant Hematopoiesis

Xia Wu  1 , Wu Ye  1 , Yuping Gong  1
Affiliations
Review

The Role of RNA Methyltransferase METTL3 in Normal and Malignant Hematopoiesis

Xia Wu et al. Front Oncol. .

Abstract

m6A modification is the most common modification in eukaryotes. METTL3, as a core methyltransferase of m6A modification, plays a vital role in normal and malignant hematopoiesis. Recent studies have shown that METTL3 is required for normal and symmetric differentiation of hematopoietic stem/progenitor cells (HSPCs). Moreover, METTL3 strongly impacts the process and development of hematological neoplasms, including the differentiation, apoptosis, proliferation, chemoresistance, and risk of tumors. Novel inhibitors of METTL3 have been identified and studied in acute myeloid leukemia (AML) cells. STM2457, a selective inhibitor of METTL3, has been identified to block proliferation and promote differentiation and apoptosis of AML cells without impacting normal hematopoiesis. Therefore, in our present review, we focus on the structure of METTL3, the role of METTL3 in both normal and malignant hematopoiesis, and the potential of METTL3 for treating hematological neoplasms.

Keywords: METTL3; N6-methyladenosine; inhibitor; malignant hematopoiesis; normal hematopoiesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The process of m6A modification. m6A RNA methylation is regulated by “writers”, “erasers”, and “readers”. MAOCM, m6A-METTL-associated complex, composed of WTAP, VIRMA, RBM15/15B, and ZC3H13.
Figure 2
Figure 2
Structure of the METTL3-METLL14 complex.
See this image and copyright information in PMC

References

    1. Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. . The Role of M6a Modification in the Biological Functions and Diseases. Signal Transduct Target Ther (2021) 6(1):74. doi: 10.1038/s41392-020-00450-x - DOI - PMC - PubMed
    1. Jones PA, Issa JP, Baylin S. Targeting the Cancer Epigenome for Therapy. Nat Rev Genet (2016) 17(10):630–41. doi: 10.1038/nrg.2016.93 - DOI - PubMed
    1. Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N(6)-Methyladenosine Modification in Cancers: Current Status and Perspectives. Cell Res (2018) 28(5):507–17. doi: 10.1038/s41422-018-0034-6 - DOI - PMC - PubMed
    1. Desrosiers R, Friderici K, Rottman F. Identification of Methylated Nucleosides in Messenger RNA From Novikoff Hepatoma Cells. Proc Natl Acad Sci USA (1974) 71(10):3971–5. doi: 10.1073/pnas.71.10.3971 - DOI - PMC - PubMed
    1. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. . N6-Methyladenosine in Nuclear RNA Is a Major Substrate of the Obesity-Associated FTO. Nat Chem Biol (2011) 7(12):885–7. doi: 10.1038/nchembio.687 - DOI - PMC - PubMed

LinkOut - more resources